Hawkins (HWKN) Q3 2026 earnings review
Acquisitions Fuel Top Line, But Integration Costs and Food Weakness Drag EPS
Hawkins posted 'record' revenue of $244.1M (+8% YoY), driven by aggressive M&A in Water Treatment (+21%). However, the growth story is expensive: higher amortization and interest expenses from the WaterSurplus deal pushed GAAP EPS down 4% to $0.69. While Industrial Solutions showed resilience (+10%), the newly formed Food & Health Sciences segment is a significant drag, shrinking 10% amid pricing pressures. The company is effectively de-leveraging (1.47x), but the divergence between revenue growth and shrinking earnings is a near-term headwind.
🐂 Bull Case
The core Water Treatment segment is accelerating, up 21% YoY to $120.5M. This wasn't just M&A; management cited improved pricing in legacy businesses alongside the $19M contribution from acquisitions.
Industrial Solutions defied macro headwinds, growing 10% YoY. Profitability in this segment surged, with operating income up 47% to $4.0M, driven by better product mix.
🐻 Bear Case
The Food & Health Sciences segment is reversing sharply. Revenue fell 10% and Gross Profit dropped 15% due to volume declines and pricing pressure. Management expects these pressures to persist into Q4.
Despite 'record' EBITDA, GAAP EPS has declined for two consecutive quarters (-7% in Q2, -4% in Q3). The WaterSurplus acquisition is currently a $4-5M quarterly drag on earnings due to amortization and interest.
⚖️ Verdict: ⚪
Neutral. The strategic pivot to Water is working on the top line, but the earnings drag from integration and the sudden weakness in the Food segment (29% of sales) create a mixed picture. Execution on the FY27 accretion target is key.
Key Themes
Food & Health Sciences Reversal
A significant negative shift occurred in the Food & Health Sciences segment. After growing 2% in Q2, revenue collapsed 10% YoY in Q3. More concerning is the margin compression: Gross Profit fell 15% and Operating Income plummeted 33%. Management explicitly flagged 'pricing pressures within food end markets' that are expected to continue into Q4.
Water Treatment M&A Strategy
The rollup strategy is the primary growth engine. Water Treatment sales grew 21% ($20.7M increase), with $19M coming directly from acquisitions (WaterSurplus, Redbird, etc.). While currently dilutive to EPS due to non-cash charges, the segment's Operating Income grew 31% to $12.8M, proving the underlying leverage of the acquired assets.
Integration Drag on EPS
The WaterSurplus acquisition is masking operational strength. The deal added ~$5M in amortization and interest expense this quarter. Management notes that Pro Forma EPS (excluding these impacts) would have grown 10% YoY. Investors must wait until FY27 for this deal to flip to accretive.
Industrial Solutions Recovery
The Industrial segment has stabilized and returned to growth. Revenue increased 10% YoY (stable vs +11% in Q2), but notably, Gross Margin expanded from 13% to 14%, driving a 47% increase in Operating Income. This segment provides critical cash flow to fund the Water pivot.
Rapid De-leveraging
Despite heavy M&A activity, Hawkins is rapidly repairing its balance sheet. The leverage ratio dropped to 1.47x from 1.53x in Q2 (and 1.61x in Q1). The company paid down $15M in debt during the quarter while maintaining a healthy cash position of $8.2M.
Other KPIs
Stable. Margins held flat YoY (21.4% in 25Q3 vs 20.8% in 26Q3). The mix shift is evident: Water Treatment margin is robust at 25%, while Industrial lags at 14%. The concern is the Food segment, where margin compressed to 20% from 21%.
Decelerating. Growth slowed to +3% YoY, down from +9% in Q2 and +13% in Q1. While positive, the slowing growth rate suggests the base business (ex-acquisitions) is facing headwinds, specifically in Food.
Strong. Cash generation remains a highlight, funding a $15M debt paydown and ongoing dividends ($0.19/share). Operating cash flow has been sufficient to absorb working capital needs despite the acquisition integration.
Guidance
Reiterated. Management confirmed the acquisition will turn accretive in Fiscal 2027 (starts April 2026), ending the current drag on EPS.
Negative trend expected to continue. Management explicitly stated they 'will continue to see pricing pressures within food end markets' in Q4.
Stable. Consistent with year-to-date performance (27% in Q3).
Key Questions
Food & Health Sciences Turnaround
Revenue in the Food segment dropped 10% with a sharp decline in operating leverage. Is this purely macro pricing pressure, or are you losing share? When do you expect this segment to bottom?
Organic vs. Inorganic Water Growth
Water Treatment grew 21%, with $19M from acquisitions. This implies organic growth was relatively flat (~$1.7M or ~1.7%). What is the organic volume trend in the legacy Water business excluding price?
Gross Margin Pressure
With the shift toward higher-value Water Treatment (25% GM) and away from Industrial, why hasn't consolidated Gross Margin expanded more significantly (flat at ~21%)? Are integration costs hitting COGS?